Raptor Set To Fly As Commercial Company With Procysbi Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Procysbi was approved by FDA April 30 for the ultra-rare disease nephropathic cystinosis and will be priced in line with other orphan drugs at an average annual cost per patient of $250,000.
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Darzalex Surpasses Stelara As J&J’s Best-Selling Drug
Sales of Stelara are expected to begin tapering off later this year when the first biosimilars launch in mid-2024 in Europe and later in the US.